



1642

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

| | |
|------------------------|------------------------|
| Application Number | 09/856,812-Conf. #3475 |
| Filing Date | September 7, 2001 |
| First Named Inventor | Lang-Qing Huang |
| Art Unit | 1642 |
| Examiner Name | M. T. B. Davis |
| Attorney Docket Number | L0461.70115US00 |

ENCLOSURES (Check all that apply)

- | | | |
|---|---|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance Communication to TC |
| <input checked="" type="checkbox"/> Fee Attached | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Petition | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Terminal Disclaimer | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Request for Refund | Form PTO-1449; International Search Report for PCT/B99/02018; References Cited; Check in the amount of \$180.00; Return Receipt Postcard |
| <input checked="" type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> Landscape Table on CD | |
| <input type="checkbox"/> Reply to Missing Parts/Incomplete Application | Remarks | |
| <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | | | |
|--------------|--------------------------------|----------|--------|
| Firm Name | WOLF, GREENFIELD & SACKS, P.C. | | |
| Signature | | | |
| Printed name | John R. Van Amsterdam | | |
| Date | July 9, 2007 | Reg. No. | 40,212 |

Certificate of Mailing Under 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 9, 2007

Signature:

(Sylvia Householder)



PTO/SB/17 (05-07)

Approved for use through 06/31/2007. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | | | |
|---|---------------------|--------------------------|------------------------|
| Effective on 12/08/2004. Pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). | | Complete if Known | |
| FEE TRANSMITTAL For FY 2007 | | Application Number | 09/856,812-Conf. #3475 |
| | | Filing Date | September 7, 2001 |
| | | First Named Inventor | Lang-Qing Huang |
| | | Examiner Name | M. T. B. Davis |
| | | Art Unit | 1642 |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27 | Attorney Docket No. | L0461.70115US00 | |
| TOTAL AMOUNT OF PAYMENT | | (\$) 180.00 | |

| | |
|---|---|
| METHOD OF PAYMENT (check all that apply) | |
| <input checked="" type="checkbox"/> Check | <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> None <input type="checkbox"/> Other (please identify): _____ |
| <input type="checkbox"/> Deposit Account Deposit Account Number: <u>23/2825</u> Deposit Account Name: <u>Wolf, Greenfield & Sacks, P.C.</u> | |
| For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) | |
| <input type="checkbox"/> Charge fee(s) indicated below | <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee |
| <input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 | <input checked="" type="checkbox"/> Credit any overpayments |

| | | | | | | | | | |
|--|---------------------|---------------------|---------------------|-----------------------|-------------------------|----------------------------------|-----------------------|-----------------------|--|
| FEE CALCULATION | | | | | | | | | |
| 1. BASIC FILING, SEARCH, AND EXAMINATION FEES | | | | | | | | | |
| | FILING FEES | | SEARCH FEES | | EXAMINATION FEES | | | | |
| | Small Entity | | Small Entity | | Small Entity | | | | |
| Application Type | Fee (\$) | Fee (\$) | Fee (\$) | Fee (\$) | Fee (\$) | Fee (\$) | Fees Paid (\$) | | |
| Utility | 300 | 150 | 500 | 250 | 200 | 100 | | | |
| Design | 200 | 100 | 100 | 50 | 130 | 65 | | | |
| Plant | 200 | 100 | 300 | 150 | 160 | 80 | | | |
| Reissue | 300 | 150 | 500 | 250 | 600 | 300 | | | |
| Provisional | 200 | 100 | 0 | 0 | 0 | 0 | | | |
| 2. EXCESS CLAIM FEES | | | | | | | Small Entity | | |
| Fee Description | | | | | | | Fee (\$) | Fee (\$) | |
| Each claim over 20 (including Reissues) | | | | | | | 50 | 25 | |
| Each independent claim over 3 (including Reissues) | | | | | | | 200 | 100 | |
| Multiple dependent claims | | | | | | | 360 | 180 | |
| Total Claims | | Extra Claims | Fee (\$) | Fees Paid (\$) | | Multiple Dependent Claims | | | |
| _____ - 20 = _____ | | x _____ | = _____ | _____ | | Fee (\$) | | Fees Paid (\$) | |
| HP = highest number of total claims paid for, if greater than 20. | | | | | | | | | |
| Indep. Claims | | Extra Claims | Fee (\$) | Fees Paid (\$) | | | | | |
| _____ - 3 = _____ | | x _____ | = _____ | | | | | | |
| HP = highest number of independent claims paid for, if greater than 3. | | | | | | | | | |

| | | | | |
|---|---------------------|---|-----------------|-----------------------|
| 3. APPLICATION SIZE FEE | | | | |
| If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). | | | | |
| Total Sheets | Extra Sheets | Number of each additional 50 or fraction thereof | Fee (\$) | Fees Paid (\$) |
| _____ - 100 = _____ | /50 = _____ | (round up to a whole number) x _____ | = _____ | |
| 4. OTHER FEE(S) | | | | |
| Non-English Specification, \$130 fee (no small entity discount) | | | | Fees Paid (\$) |
| Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement | | | | 180.00 |

| | | | |
|---------------------|------------------------------|-----------------------------------|----------------|
| SUBMITTED BY | | | |
| Signature | <i>John R. Van Amsterdam</i> | Registration No. (Attorney/Agent) | 40,212 |
| Name (Print/Type) | John R. Van Amsterdam | Telephone | (617) 646-8000 |
| | | Date | July 7, 2007 |

| | |
|---|---|
| Certificate of Mailing Under 37 CFR 1.8(a) | |
| I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. | |
| Date: <u>July 9, 2007</u> | Signature: <i>[Signature]</i> (Sylvana Householder) |



DOCKET NO.: L0461.70115US00


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lan-Qing Huang et al.
Serial No.: 09/856,812
Confirmation No.: 3475
Filed: September 7, 2001
For: TUMOUR REJECTION ANTIGENS

Examiner: Davis, Minh Tam B.
Art Unit: 1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 9th day of July, 2007.


Sylvia Householder

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office action, but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

07/11/2007 EAYALEW1 00000028 09856612

01 FC:1806

180.00 00

1211338.1

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant would like to bring to the Examiner's attention the enclosed search report from a corresponding International or Foreign National Application.

**International Search Report for International Application No. PCT/IB99/02018,
mailed June 27, 2000.**

The following are remarks concerning the other information cited:

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Serial No.: 09/856,812
Conf. No.: 3475

- 3 -

Art Unit: 1642


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:


John R. Van Amsterdam, Ph.D.
Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: L0461.70115US00
Date: July 7, 2007
xNDDx



FOR PTO-1449/ and B (modified PTO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| | | | | | |
|-------|--|----|--|----------------------------------|-----------------------------------|
| Sheet | | of | | APPLICATION NO.: 09/856,812 | ATTY. DOCKET NO.: L0461.70115US00 |
| | | | | FILING DATE: September 7, 2001 | CONFIRMATION NO.: 3475 |
| | | | | APPLICANT: Lan-Qing Huang et al. | |
| | | | | GROUP ART UNIT: 1642 | EXAMINER: Davis, Minh Tam B. |

U.S. PATENT DOCUMENTS

| Examiner's Initials * | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or Issue of Cited Document MM-DD-YYYY |
|--------------------------|-------------|----------------------|--------------|--|---|
| | | Number | Kind Code | | |
| /T.D./ | A1 | 5,686,068 | A | Boon-Falleur et al. | 22-11-1997 |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials * | Cite No. | Foreign Patent Document | | | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|--------------------------|-------------|-------------------------|----------|--------------|---|----------------------|
| | | Office/ Country | Number | Kind Code | | |
| /T.D./ | B1 | WO | 98/14463 | A | Ludwig Institute for Cancer Research | 04-09-1998 |
| ↓ | B2 | WO | 95/25530 | A | Ludwig Institute for Cancer Research; Univ Leiden | 09-28-1995 |
| | B3 | WO | 99/54738 | A | Ludwig Institute for Cancer Research | 10-28-1999 |
| | B4 | WO | 99/61916 | A | Epimmune, Inc. | 12-02-1999 |
| | B5 | WO | 92/20356 | A | Ludwig Institute for Cancer Research | 11-26-1992 |
| | B6 | WO | 99/45954 | A | Eppimmune, Inc. | 09-16-1999 |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials * | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|--------------------------|-------------|---|----------------------|
| /T.D./ | C1 | CHEN, YAO-TSENG et al., "Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library," <i>Proc. Natl. Acad. Sci. USA</i> June 1998; 95:6919-6923. | |
| ↓ | C2 | COULIE, P.G., "Antigens Recognized on Human Tumors by Cytolytic T Lymphocytes: Towards Vaccination?" <i>Stem Cells</i> 1995; 13(4):393-403. | |
| | C3 | DABOVIC, B. et al., "A family of rapidly evolving genes from the sex reversal critical region in Xp21," <i>Mammalian Genome</i> 1995; 6:571-580. | |
| | C4 | DE PLAEN, ETIENNE et al., "Structure, chromosomal localization, and expression of 12 genes of the MAGE family," <i>Immunogenetics</i> 1994; 40:360-369. | |

| | |
|--|------------------|
| EXAMINER: /Minh Tam Davis/ (11/13/2007) | DATE CONSIDERED: |
|--|------------------|

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE — No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

| | | | |
|--|--|----------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) | | APPLICATION NO.: 09/856,812 | ATTY. DOCKET NO.: L0461.70115US00 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FILING DATE: September 7, 2001 | CONFIRMATION NO.: 3475 |
| | | APPLICANT: Lan-Qing Huang et al. | |
| | | GROUP ART UNIT: 1642 | EXAMINER: Davis, Minh Tam B. |
| Sheet | | of | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials # | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|--------------------------|------------|---|----------------------|
| /T.D./ | C5 | GAUGLER, BEATRICE et al., "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes," <i>J. Exp. Med.</i> 1994; 179:921-930. | |
| | C6 | GILBERT, SARAH C. et al., "A protein particle vaccine containing multiple malaria epitopes," <i>Nature Biotechnology</i> November 1997; 15:1280-1284. | |
| | C7 | HAAS, GILBERT G. et al., "Distribution of Human Leukocyte Antigen-ABC and -D/DR Antigens in the Unfixed Human Testis," <i>American Journal of Reproductive Immunology and Microbiology</i> 1988; 18:47-51. | |
| | C8 | HU, XUEYOU et al., "Enhancements of Cytolytic T Lymphocyte Precursor Frequency in Melanoma Patients following Immunization with the MAGE-1 Peptide Loaded Antigen Presenting Cell-based Vaccine," <i>Cancer Research</i> June 1, 1996; 56:2479-2483. | |
| | C9 | HUANG, LAN-QING et al., "Cytolytic T Lymphocytes Recognize an Antigen Encoded by MAGE-A10 on a Human Melanoma," <i>The Journal of Immunology</i> 1999; 162:6849-6854. | |
| | C10 | LUCAS, SOPHIE et al., "Identification of a New Mage Gene with Tumor-specific Expression by Representational Difference Analysis," <i>Cancer Research</i> February 15, 1998; 58:743-752. | |
| | C11 | LURQUIN, CHRISTOPHE et al., "Two Members of the Human MAGEB Gene Family Located in Xp21.3 Are Expressed in Tumors of Various Histological Origins," <i>Genomics</i> 1997; 46:397-408. | |
| | C12 | MARCHAND et al., "Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3," <i>Int. J. Cancer</i> 1995; 63:883-885. | |
| | C13 | MUKHERJI, BIJAY et al., "Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells," <i>Proc. Natl. Acad. Sci. USA</i> August 1995; 92:8078-8082. | |
| | C14 | MUSCATELLI, F. et al., "Isolation and characterization of a MAGE gene family in the Xp21.3 region," <i>Proc. Natl. Acad. Sci. USA</i> May 1995; 92:4987-4991. | |
| | C15 | NESTLE, FRANK O. et al., "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," <i>Nature Medicine</i> March 1998; 4(3):328-332. | |
| | C16 | RAMMENSEE, HANS-GEORG et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> 1995; 41:178-228. | |
| | C17 | RIMOLDI, DONATA et al., "cDNA and Protein Characterization of Human MAGE-10," <i>Int. J. Cancer</i> 1999; 82:901-907. | |

| | |
|--|------------------|
| EXAMINER: /Minh Tam Davis/ (11/13/2007) | DATE CONSIDERED: |
|--|------------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

| | | | |
|--|--|----------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) | | APPLICATION NO.: 09/856,812 | ATTY. DOCKET NO.: L0461.70115US00 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FILING DATE: September 7, 2001 | CONFIRMATION NO.: 3475 |
| | | APPLICANT: Lan-Qing Huang et al. | |
| | | GROUP ART UNIT: 1642 | EXAMINER: Davis, Minh Tam B. |
| Sheet | | of | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials # | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|-----------------------|---------|---|-------------------|
| /T.D./ | C18 | TAM, JAMES P. et al., "Incorporation of T and B Epitopes of the Circumsporozoite Protein in a Chemically Defined Synthetic Vaccine Against Malaria," <i>J. Exp. Med.</i> January 1990; 171:299-306. | |
| | C19 | THOMSON, SCOTT A. et al., "Minimal epitopes expressed in a recombinant polypeptide protein are processed and presented to CD8+ cytotoxic T cells: Implications for vaccine design," <i>Proc. Natl. Acad. Sci. USA</i> June 1995; 92:5845-5849. | |
| | C20 | TRAVERSARI, CATIA et al., "A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed against Tumor Antigen MZ2-E," <i>J. Exp. Med.</i> November 1992; 176:1453-1457. | |
| | C21 | UYTTENHOVE, CATHERINE et al., "The Expression of Mouse Gene P1A in Testis Does Not Prevent Safe Induction of Cytolytic T Cells Against a P1A-Encoded Tumor Antigen," <i>Int. J. Cancer</i> 1997; 70:349-356. | |
| | C22 | VAN DEN EYNDE, B. et al., "Presence on a Human Melanoma of Multiple Antigens Recognized by Autologous CTL," <i>Int. J. Cancer</i> 1989; 44:634-640. | |
| | C23 | VAN DER BRUGGEN, PIERRE et al., "Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601*," <i>Eur. J. Immunol.</i> 1994; 24:2134-2140. | |
| | C24 | VAN DER BRUGGEN, P. et al., "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma," <i>Science</i> 13 December 1991; 254:1643-1647. | |
| | C25 | VAN DEN EYNDE, BENOIT J. et al., "T cell defined tumor antigens," <i>Current Opinion in Immunology</i> 1997; 9:684-693. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | |
|--|------------------|
| EXAMINER: /Minh Tam Davis/ (11/13/2007) | DATE CONSIDERED: |
|--|------------------|

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE — No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]